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Edited by Sandro SonninoAbstract Association of protein inclusions or aggregates within
brain tissues of patients with neurodegenerative disorders has
been widely reported. These inclusions are commonly character-
ised both by the presence of ubiquitylated proteins and the
sequestration of components of the ubiquitin–proteasome system
(UPS). Such observations have led to the proposition that the
UPS has a direct role in their formation. Indeed, the presence
of ubiquitylated proteins and UPS components in inclusions
may reﬂect unsuccessful attempts by the UPS to remove aggre-
gating proteins. Whether the physical presence of inclusions
causes cell death or, conversely, whether they are non-toxic
and their presence reﬂects a cellular protective mechanism re-
mains highly controversial.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Neurodegenerative disorders, including Alzheimers (AD)
and Parkinsons (PD) diseases, are characterised by a selective
loss of neurons in speciﬁc, but diﬀerent, regions of the brain.
The result is often a disruption to motor, sensory or cognitive
systems, resulting in severe disability of the patient.
The pathological characteristic of many neurodegenerative
diseases is the presence of distinctive ubiquitin-positive, intra-
or extracellular, inclusion bodies in aﬀected regions of the brain
(Table 1). In general, these inclusions consist of insoluble, un-
folded, ubiquitylated polypeptides that fail to be targeted and
degraded by the 26S proteasome [1,2]. Their apparent stability
may, in part, be due to decreased levels of 26S proteasomal activ-
ity that is associated with increasing age [3]. Given the patholog-
ical presentation of these conditions, it has not been altogether a
major surprise to ﬁnd that proteins associated with the UPS are
now known to play either a direct or indirect role in familial
forms of neurodegenerative disease and, in particular, PD.2. The Ubiquitin–proteasome system
UPS-mediated post-translational modiﬁcation and degrada-
tion of proteins is essential for most cellular processes such as*Corresponding author.
E-mail address: h.c.ardley@leeds.ac.uk (H.C Ardley).
0014-5793/$30.00  2005 Published by Elsevier B.V. on behalf of the Feder
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apoptosis. Historically, it was recognised that the UPS is the
major route by which proteins are selected for temporal and
spatial degradation in eukaryotic cells [for recent reviews, see
4,5].
The covalent attachment of the seventy-six amino acid resi-
due protein, ubiquitin, to an e-amino group of a lysine residue
in a target protein involves an energy-dependent, four-step
pathway (Fig. 1). The UPS cascade requires transfer of ubiqui-
tin from an ubiquitin-activating enzyme (E1) to an ubiquitin-
conjugating enzyme (E2) and then to the target substrate
protein facilitated by an ubiquitin-protein ligase (E3). Multiple
rounds of ubiquitylation (generally through covalent attach-
ment to ubiquitin Lys48) may occur, leading to the generation
of polyubiquitin chains. Polyubiquitylated substrates are then
selected for degradation by the 26S proteasome. At least four
ubiquitin molecules must be attached to activate proteasomal
mediated degradation. During proteasomal proteolysis ubiqui-
tin is removed and recycled, and the target protein broken
down into small peptides. These latter molecules can be hydro-
lysed further by other cellular peptidases or processed for
MHC class 1 antigen presentation [6].
Until recently, the requirement for the addition of multiple
ubiquitin molecules had remained somewhat of a mystery. It
may provide a cellular proof-reading mechanism to protect
certain proteins from degradation as a large number of de-
ubiquitylating enzymes (DUBs) are also found within cells
[7]. For such substrates, DUBs remove ubiquitin moieties be-
fore a suﬃciently long ubiquitin chain has been synthesised
to activate proteasomal destruction. Monoubiquitylation of
proteins may also occur. This process appears to regulate
endocytosis of cell surface receptors, DNA repair mechanisms,
histone methylation and transcription regulation [8].
Several ubiquitin-like (Ubl) proteins such as SUMO and
NEDD8 also covalently tag proteins [9,10]. However, in gen-
eral, only single molecules are attached. Each requires its own
unique combination of E1, E2 and E3. The addition of these
tags does not target proteins for degradation, but has roles in
activation of gene transcription, maintenance of multiprotein
complex structures, protein localisation and protein stability.3. Inclusion formation and the nature of aggresomes
The key constituents of the inclusions associated with neuro-
degenerative disorders are mis-folded proteins (Fig. 2). Theation of European Biochemical Societies.
Fig. 1. Protein mediated degradation via the ubiquitin–proteasome pathway. Ubiquitylation occurs in a step-wise manner. An energy dependent
thioester bond forms between the C-terminal glycine residue of ubiquitin (Ub) and a thiol group located within an ubiquitin-activating enzyme (E1).
Ubiquitin is then transferred to an ubiquitin-conjugating enzyme (E2) via transthiolation. Ubiquitin-protein ligases (E3s) then facilitate
ubiquitylation of the substrate protein (S). Several classes of E3s exist, most are either RING or HECT type E3s. HECT E3s transfer ubiquitin
directly to the substrate, whereas RING E3s do not directly catalyse the target protein and may require the presence of additional components,
including the E2, for ubiquitylation to proceed. Multiple ubiquitin molecules may then be covalently attached to one of several lysine residues found
within a pre-attached ubiquitin to form a polyubiquitylated protein. Chains of at least four ubiquitin molecules are required for recognition by the
26S proteasome. Prior to ATP dependent proteasomal degradation, ubiquitins are removed from the substrate by one of many DUBs found within
cells and the ubiquitin recycled for further targeted degradation. UPS components which can be mutated/dysfunctional in neurodegeneration are
shown in red.
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function are mis-sense mutations, modiﬁcations or post-
translational damage of proteins, or expansion of amino acid
repeats as is observed in polyglutamine (polyQ) disorders such
as Huntingtons disease (HD).
The presence of these protein aggregates is somewhat puz-
zling given that the chaperone system and the UPS are de-
signed to prevent such events occurring. Indeed, these
inclusions are commonly associated with ubiquitin staining,
indicating that cellular protective mechanisms attempt, yet
somehow fail, to remove these abnormal proteins. Minor
changes to the eﬃciency of the balance between synthesis
and degradation may have disastrous long-term consequences
for cells. These problems would be particularly acute in termi-
nally diﬀerentiated non-renewing cell populations such as
neurons.Table 1
Neurodegenerative disorders associated with ubiquitylated inclusions
Neurodegenerative disease Type of ubiquitylated inclusion
Alzheimers Amyloid plaques and
neuroﬁbrillary tangles
Parkinsons Lewy bodies
Amyotrophic Lacteral sclerosis Hydraline and skein-like
Huntingtons and other PolyQ Ubiquitylated inclusions
Picks Picks bodies
Lafora Starch-like polyglucosans
(Lafora bodies)Inclusions are routinely characterised by the presence of one
major core protein, or peptide, such as a-synuclein (the major
constituent of Lewy bodies in PD) or b-amyloid peptide (Ab,
associated with the plaques of AD). It is assumed that these
proteins provide the seed of an inclusion. However, inclusions
are also characterised by a myriad of other proteins present at
lower abundance, which are thought to be sequestered into
inclusions as they form. These latter components often include
chaperones [11,12], UPS components [1,13] and cytoskeletal
elements [14,15]. In addition to seeding inclusion formation,
mutant (but not wild-type) a-Synuclein and Ab are capable
of inhibiting proteasome activity, further exacerbating the
problem [16,17].
In vitro cell culture systems are able to replicate many prop-
erties of neuronal inclusion formation. Using such systems,
overexpression of a number of neurodegenerative disease-asso-
ciated proteins, including Presenilin 1, Parkin and Huntingtin
(associated with AD, PD and HD, respectively) leads to inclu-
sion formation in the presence of proteasome inhibitors
[18–21]. Moreover, many disease-associated mutant proteins
readily form aggregates without the need for proteasome
inhibition [20,21].
These inclusions have been characterised as aggresomes
[18,22]. It is postulated that aggresome formation is a protec-
tive cellular response to overloading of the proteasome [18].
They commonly contain chaperones, UPS components, centr-
osomal material and cytoskeletal proteins [18–22]. Most aggre-
somes are delivered in a microtubule-dependent manner to the
Fig. 2. Potential routes for the formation of inclusion bodies. Proteins which are not degraded by proteolysis may aggregate to form inclusion
bodies. Under normal cellular conditions, functional proteins are generated through the correcting folding or refolding of proteins by molecular
chaperones. The formation of aggregates may be prevented by degradation by the proteasome. Blockage of proteasomes by mis-folded protein may
cause protein accumulation and aggregation that leads to the formation of inclusion bodies.
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by a vimentin cage [18,22]. McNaught and colleagues [23] re-
cently proposed that Lewy bodies represent a specialised
aggresome-related inclusion speciﬁc to dopaminergic neurons.4. Neurodegenerative diseases and the malfunction of the UPS
Probably, the strongest evidence for a signiﬁcant role of the
UPS in these debilitating neurodegenerative diseases has come
from genetic studies. Abnormal expression of these mutant
proteins in combination with an age-related decline in protea-
some activity provides a molecular explanation for the age-
related nature of these disorders [3].
Ubiquitin itself does not escape aberrant properties as our
cellular functions grow old. Molecular-misreading occurs
when one or more base pairs are lost during the transcriptional
process. In some AD patients, novel frameshift mutations in
the ubiquitin B gene lead to translation of novel but nonsense
peptide sequences creating ubiquitin + 1 [24,25]. Ubiqui-
tin + 1 can accept additional ubiquitin molecules but cannot
donate itself to an expanding polyubiquitin chain as it lacks
its C-terminal glycine residue. This mutant form of ubiquitin
blocks proteasomal degradation [24] and causes neuronal cell
death [25].
To date, the E3 family appears to be the major group of
components of the UPS to be aﬀected in neurodegenerative
disease (Fig. 1) [for recent review, see 26]. This is perhaps
not surprising given that relatively few E1s and E2s exist in
mammals. By contrast, there are potentially hundreds of E3sto be found within the human genome, the majority of which
remain uncharacterised. Such a variety of E3s allows precise
targeting of each (post-translationally modiﬁed) substrate at
a given time or localisation within each cell in response to
many diﬀerent stimuli.
Multiple E3s may be involved in a single disease. Con-
versely, one E3 may play a part in more than one disease.
For example, Parkin plays a signiﬁcant role in PD, but may
also provide a protective role in polyQ disorders [27]. Simi-
larly, Dorﬁn is required to remove mutant SOD1 in the motor
neuron disorder, Amyotrophic Lacteral Sclerosis, but may also
be involved in synphilin-1 clearance in PD [28]. The patholog-
ical signiﬁcance of such interplay between E3s as causative
events in disease remains to be elucidated.
The most widely studied DUB associated with neurodegen-
eration is UCH-L1 (PGP 9.5), a protein highly abundant in
neuronal cells [29]. Surprisingly, it was recently discovered that
UCH-L1 also possesses a dimerisation dependent E3 activity
towards a-synuclein in vitro [30]. UCH-L1 has been localised
to inclusions associated with PD, AD and the Rosenthal ﬁbres
associated with cerebellar astrocytomas [31]. Moreover, diﬀer-
ent isoforms may play pathological or protective roles in AD,
PD and HD [32–34]. The gad mouse is unable to express the
murine orthologue of UCH-L1. Pathologically, it displays neu-
ronal degeneration with progressive accumulation of Ab and
ubiquitin-positive inclusions along sensory and motor neurons
[35]. These ﬁndings provide additional evidence that altered
function of the UPS directly causes neurodegeneration, the
gad mouse thus represents an ideal model in which to study
the role of the UPS in such disorders.
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mal activity in cells declines [3]. The consequence is likely to be
less eﬃcient clearance of proteins by the UPS. Presence of mu-
tant and/or aggregated proteins is likely to compound these
adverse eﬀects by physically blocking entrance to the protea-
some, further reducing its activity. As well as general blocking
of the proteasome, some neurodegenerative disease associated
proteins such as Ataxin-7, a polyQ containing protein associ-
ated with spinocerebellar ataxia type 7, can interact with 19S
regulatory proteasomal subunits [36]. The 19S regulatory com-
plex is responsible for recognition and binding of substrates
prior to their entry into the 20S catalytic core of the protea-
some. Expanded polyQs of Ataxin-7 bind poorly with the
S4 subunit of the 19S regulatory complex suggesting that this
may cause further interference of normal proteasomal
functions.
4.1. Parkinsons disease
Of all the neurodegenerative diseases, PD is most closely
associated with aberrant protein processing via the UPS. In-
deed, of the known proteins associated with hereditary forms
of PD, Parkin and UCH-L1 are components of the UPS,
whereas modiﬁed and/or mutant a-Synuclein and DJ-1 are de-
graded by the system [37–41].
Hereditary mutations within the gene encoding Parkin cause
loss of E3 activity without formation of the Lewy bodies [42].
A number of Parkin substrates have been identiﬁed including
a-Synuclein [40] and/or a glycosylated form of a-Synuclein,
termed a Sp22 [39]. Nonetheless, the signiﬁcance of Parkin tar-
geted ubiquitylation of these proteins with respect to PD re-
mains largely unclear, since Parkin/ mice display normal
levels of a number of its known substrates [43]. Such observa-
tions may in part be due to a redundancy in substrate targeting
by E3s such as CHIP, Dorﬁn and Siah-1, which are capable of
targeting the removal of some of Parkins substrates [28,44,45].
Mutations in the DUB UCH-L1, which drastically reduce its
enzymatic activity, cause autosomal dominant PD in a Ger-
man kindred [38]. Although it remains to be established
whether these patients have Lewy bodies, the disease causing
mutation has a high propensity to form aggresomes when
overexpressed in vitro relative to the wild-type isoform [46].5. Neurodegenerative inclusions: toxic or protective?
Over the years, there has been much debate regarding the
presence of inclusions in neuronal cells of neurodegenerative
disease patients. Do they reﬂect the results of a protective re-
sponse mechanism to some yet to be identiﬁed adverse envi-
ronmental challenge? Are they, or their precursors, toxic or
non-toxic? In PD, inclusions are only found in the surviving
neurons of the diseased patients. Did the dopaminergic neu-
rons that have died once contain toxic inclusions? Or were
non-surviving cells unable to form inclusions to protect them-
selves from toxic entities resulting in their death?
The results of recent studies indicate that the Toxic or
Protective? argument is probably a simplistic view of what
is happening inside patients aﬀected cells. Recent studies
have indicated that prolonged low-level proteasome inhibi-
tion causes buildup of aggregated protein species within neu-
ronal cells in vitro [47]. In addition, exposure to proteasome
inhibitors in rats caused progressive parkinsonism withdopaminergic cell loss [48]. Furthermore, studies of aggre-
gate prone proteins such as Ab indicate that mis-folded
intermediates, or protoﬁbrils, generated during the produc-
tion of amyloid ﬁbrils (which may subsequently form AD
plaques) are highly toxic, possibly more so than the ﬁbril
itself [49,50]. Indeed, there is increasing evidence that inclu-
sions and aggresomes are cytoprotective [e.g. 51,52] and may
activate autophagy in order to remove the mutant protein
[53,54].
In summary, it appears likely that the protoﬁbrillar form of
many neurodegenerative disease associated proteins may be
guilty of causing rapid cell death (hence, inherited forms of
these disorders tend to have an earlier onset than the sporadic
forms). Yet if the protoﬁbrils can be made to aggregate rapidly
into inclusions, the cell becomes somewhat protected from the
damage these toxic entities cause and may even be able to clear
the aggregate via the proteasome or autophagy. In the longer
term, however, aggregation may exceed clearance of proteins
and cause cellular death.6. Concluding remarks
The UPS is by no means the only culprit in the causation of
neurodegeneration. Although their precise roles in disease re-
main unclear, ubiquitin related proteins such as SUMO and
the ubiquitin binding protein p62 are common constituents
of the pathological inclusions associated with neurodegenera-
tive diseases [55,56].
Furthermore, similar to the proteasome, the eﬃciency of the
chaperone system is also thought to deteriorate with age [57].
Mitochondrial dysfunction and excessive production of reac-
tive oxygen species (ROS) are also known causes of neurode-
generation [58,59]. The cumulative eﬀect of ineﬃcient
chaperone and UPS activity, and a malfunctioning mitochon-
drial respiratory chain (leading to lower ATP levels and in-
creases in ROS and oxidative damage) produces a vicious
cycle. Understanding the interplay between these systems,
and where they may overlap in diﬀerent disorders, is a complex
and overwhelming task. However, it may be the only way we
can truly ﬁnd eﬃcient, disease speciﬁc, curative and preventa-
tive medicines for these debilitating conditions.
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